First author | Year | Disease | Timing of assessment | Comparison | EA |
---|---|---|---|---|---|
Kim16 | 2007 | RA | Week 24 | PBO vs ADA | No |
Rutgeerts17 | 2005 | UC | Week 54 | PBO vs IFX | Yes |
Baranauskaite18 | 2012 | PsA | Week 16 | MTX vs IFX+MTX | Yes |
Barker19 | 2011 | Ps | Week 24 | MTX vs IFX | – |
Braun20 | 2002 | AS | Week 12 | PBO vs IFX | No |
Breedveld21 | 2006 | RA | Year 2 | MTX vs ADA/ADA+MTX | – |
Chen22 | 2009 | RA | Week 12 | MTX vs ADA+MTX | No |
Colombel23 | 2010 | CD | Week 20 | AZA vs IFX/IFX+AZA | – |
Couriel24 | 2009 | GvH | Month 6 | MP vs IFX+MP | No |
Judson25 | 2014 | Sarcoidosis | Week 44 | PBO vs GOL | – |
Kavanaugh26 | 2013 | RA | Week 26 | PBO+MTX vs ADA+MTX | Yes |
Kennedy27 | 2014 | RA | Week 12 | PBO vs ADA | No |
Keystone28 | 2004 | RA | Week 52 | PBO+MTX vs ADA+MTX | No |
Keystone29 | 2008 | RA | Week 52 | PBO+MTX vs CZP+MTX | Yes |
Maini30 | 1999 | RA | Week 102 | DMARDs vs IFX+DMARDs | No |
Nam31 | 2014 | RA | Week 78 | PBO+MTX vs IFX+MTX | No |
Reich32 | 2012 | Ps | Week 12 | PBO vs CZP | No |
Schiff33 | 2014 | RA | Year 2 | ABA+MTX vs ADA+MTX | No |
Schiff34 | 2008 | RA | Year 1 | PBO+MTX vs IFX+MTX | Yes |
Sieper35 | 2014 | AS | Week 28 | PBO+NPX vs IFX+NPX | Yes |
Smolen36 | 2009 | RA | Week 24 | PBO+MTX vs CZP+MTX | Yes |
St Clair37 | 2004 | RA | Week 54 | PBO+MTX vs IFX+MTX | No |
Suzuki38 | 2014 | UC | Week 8 | PBO vs ADA | No |
Tam39 | 2012 | RA | Month 6 | MTX vs IFX+MTX | Yes |
Van Den Bosch40 | 2002 | AS | Week 12 | PBO vs IFX | - |
van der Heijde41 | 2007 | RA | Year 3 | MTX vs ETN/ETN+MTX | Yes |
van Vollenhoven42 | 2011 | RA | Week 24 | PBO+MTX vs ADA+MTX | Yes |
Wenzel43 | 2009 | Asthma | Week 76 | PBO vs GOL | No |
Westhovens44 | 2006 | RA | Week 22 | PBO+MTX vs IFX+MTX | Yes |
ABA, abatacept; ADA, adalimumab; AS, ankylosing spondylitis; AZA, azathioprine; CD, Crohn's disease; CZP, certolizumab pegol; DMARDs, disease-modifying anti-rheumatic drugs; EA, endemic area of TB; ETN, etanercept; GOL, golimumab; GvH, graft-versus-host disease; IFX, infliximab; MP, methylprednisolone; MTX, methotrexate; NPX, naproxen; PBO, placebo; Ps, plaque psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.